Disease Studies

PrecisionLife offers support to COVID-19 coronavirus research community

6/04/20

Oxford, UK – PrecisionLife has confirmed it is extending its relationships with some of the largest COVID-19 collaborative research projects and is now offering free use of its unique analytics platform and support from its data and biomedical science teams to the on-going collaborative efforts of the medical research community in the fight against COVID-19 coronavirus.


The PrecisionLife platform can analyze large scale, complex multi-omic and epidemiological data to generate disease insights that are not possible with current tools. It is routinely used to analyze very large anonymized patient datasets (>100,000 patients) and with detailed insights into complex diseases returned within hours.

The platform can be used to help:

  • Identify the complex genetic factors associated with patients’ different disease severity and outcomes
  • Understanding risk factors such as smoking, gender, ethnicity, blood group and underlying health conditions
  • Developing tests to identify whether people are at high- / low-risk for serious forms of the disease
  • Informing the hunt for existing drugs that will be effective for given patient sub-groups, especially those at risk of late-stage disease
  • Identification of novel drugs targets especially for more serious late-stage disease

To be effective, the PrecisionLife tools require data from a minimum of several hundred COVID-19 patients, ideally including genotype/whole genome sequence with additional data including disease severity, co-morbidities, and epidemiological/phenotype information such as blood group, smoking, gender, ethnicity etc. The methods work hypothesis-free and do not require training.

The PrecisionLife platform has been validated on over 20 complex disease studies and with disease specialists, development partners and in pre-clinical assays/models. Several of these studies have focused on respiratory and immune response/auto-immune diseases.

PrecisionLife believes that its tools will be particularly helpful in analyzing the COVID-19 patient datasets currently being generated, and would welcome approaches from relevant parties, both in the UK and further afield.

For more information, please contact covid-19@precisionlife.com.


More News & Media

View All News & Media

PrecisionLife unveils new spin-out Synomics taking its proven analytics platform into animal and crop health sectors

OXFORD, UK, April 7, 2021 PrecisionLife Ltd, leaders in combinatorial analytics, today unveils the launch of its new spin-out…

7/04/21
Read more

PrecisionLife continues growth and expansion with acquisition of Danish genomic analytics innovator GenoKey

OXFORD, UK, and AALBORG, Denmark, March 24, 2021 PrecisionLife today announces that it has acquired its long-term Danish technology…

24/03/21
Read more

PrecisionLife joins Nvidia Inception – the premier program for AI and data science startups

PrecisionLife will benefit from Nvidia’s Inception program that supports AI companies from “seed to unicorn” status providing the company…

15/03/21
Read more

Keep in touch

Please enter your email address if you would like to be kept informed of our work here at PrecisionLife. Note that our Privacy Policy and Terms & Conditions apply.

  • This field is for validation purposes and should be left unchanged.

Contact us

If you have any questions or would like to speak to us in terms of potential collaborations or partnership opportunities, please get in touch using the form below or email info@precisionlife.com and we will get back to you as soon as we can. Note that our Privacy Policy and Terms & Conditions apply.


UK

Unit 8b Bankside
Hanborough Business Park
Long Hanborough, OX29 8LJ

USA

1 Broadway Fl 14
Cambridge
MA 02142-1187

Denmark

Agern Allé 3
DK-2970
Hørsholm

Poland

CIC Ul
Chmielna 73m
00-801 Warszawa

  • This field is for validation purposes and should be left unchanged.